19 Jun Use of Y-90 resin microspheres offer benefits for the treatment of primary liver cancer
New APAC study findings presented at ASCO: Use of Y-90 resin microspheres offer benefits for the treatment of primary liver cancer
A new Asia-Pacific (APAC) Study presented at the 2017 American Society of Clinical Oncology Meeting (ASCO) on June 6, 2017 has revealed important treatment benefits with the use of Y-90 resin microspheres compared to sorafenib, the current standard care, for advanced Hepatocellular Carcinoma (HCC) or primary liver cancer – the sixth most common cancer worldwide.
The microspheres, administered once directly to the liver, showed a significantly better tumour response rate of 16.5% compared to the twice-daily oral doses of sorafenib. In addition, patients experienced an almost two-fold decrease in severe adverse events and one-fourth as many adverse events with the Y-90 Resin microspheres treatment compared with sorafenib.
Adverse events significantly reduced with the treatment included fatigue, diarrhoea, hand-foot skin reaction, alopecia and hypertension. Moreover, a significantly reduced rate in the incidence of direct side effects from the microspheres, such as gastric ulcer, upper GI haemorrhage, jaundice and portal hypertension, were also reported. Although there was no significant difference in the Overall Survival (OS) rate, a significant increase in the overall Progression-Free Survival rate of 6.3 months was found.
According to Professor Pierce Chow, Principal Investigator and Senior Consultant Surgeon, National Cancer Centre Singapore and the Singapore General Hospital, the comparative data on the side effects reported in the study “unequivocally favoured Y-90 resin microspheres over sorafenib.”